Consequently, the blockade of the autophagic machineryshould significantly help to prevent or retard the appearance of acquired (secondary) resistance totrastuzumab in HER2 gene-amplified breast carcinoma cells [27, 28]. This evidence concerns the gene ERBB2 and breast carcinoma.